STAT3 and breast carcinoma: Our results may bring insights to the HIF‐1α/STAT3 interaction in breast cancers and suggest sanguinarine may potentially be recognized as HIF‐1α/STAT3 targeted compound for disturbing the growth of human breast cancers.